摘要
目的比较替格瑞洛与氯吡格雷在中国冠心病患者中的安全性。方法计算机检索Pub Med、Cochrane图书馆、中国期刊全文数据库、万方数据库、维普数据库、中国生物医学文献数据库,收集2009年7月~2014年11月发表的有关替格瑞洛与氯吡格雷治疗中国冠心病患者的对照研究。分为替格瑞洛组,90 mg 2/日;氯吡格雷组,75 mg 1/日。在严格质量评价的基础上,对符合入选要求的临床研究进行资料提取,数据采用Rev Man 5.3.5软件进行Meta分析。结果纳入15篇对照研究,共计2091例受试者。Meta分析显示:替格瑞洛组与氯吡格雷组之间的出血发生率无显著差异(OR=1.31,95%CI:0.92~1.87,P=0.13),但替格瑞洛组的呼吸困难发生率显著高于氯吡格雷组(OR=2.62,95%CI:1.54~4.46,P=0.00004)。结论在中国冠心病患者中,替格瑞洛组的出血发生率与氯吡格雷组相当。
Objective To compare the safety between ticagrelor and clopidogrel in Chinese patients with coronary heart disease(CHD). Methods The databases of Pub Med, Cochrane Library, CNKI, Wan Fang Database, VIP Database and CBM were retrieved with computer for collecting the control studies about ticagrelor and clopidogrel in treatment of Chinese CHD patients from Jul. 2009 to Nov. 2014. The studies were divided into ticagrelor group(90 mg bid) and clopidogrel group(75 mg qd). On the base of strict review on quality, the data was extracted from eligible clinical studies and given a Meta-analysis by using software Rev Men 5.3.5. Results There were 15 control studies included involving 2091 patients. The results of Meta-analysis showed that the difference in incidence of bleeding was not significant between ticagrelor group and clopidogrel group(OR=1.31, 95%CI: 0.92~1.87, P=0.13), and incidence of dyspnea was significantly higher in ticagrelor group than that in clopidogrel group(OR=2.62, 95%CI: 1.54~4.46, P=0.00004). Conclusion The incidence of bleeding is similar in ticagrelor group and clopidogrel group, but incidence of dyspnea is significantly higher in ticagrelor group than that in clopidogrel group in Chinese CHD patients.
出处
《中国循证心血管医学杂志》
2015年第5期593-596,共4页
Chinese Journal of Evidence-Based Cardiovascular Medicine
基金
江苏省临床医学科技专项资助(BL2013001)
关键词
替格瑞洛
氯吡格雷
冠心病
安全性
Ticagrelor
Clopidogrel
Coronary heart disease
Safety
